Nuzee (NUZE) Announces Proposed Share Offering

NuZee, Inc. (NASDAQ: NUZE), a leading coffee co-packing and technology company, today announced it has commenced a firm commitment underwritten public offering of its common stock. All of the shares of common stock are being offered by NuZee. The public offering is subject to market and other conditions, and there can be no assurance as to whether or when the public offering may be completed, or the actual size or terms of the public offering.

Maxim Group LLC is acting as the sole book-running manager for the public offering.

The public offering is being made pursuant to an effective shelf registration statement on Form S-3 (File No. 333-274818) previously filed with the U.S. Securities and Exchange Commission (the "SEC") on September 29, 2023 and declared effective on October 5, 2023. The securities will be offered only by means of a preliminary prospectus supplement and accompanying prospectus forming a part of the effective registration statement. A preliminary prospectus supplement describing the terms of the public offering will be filed with the SEC and will be available on the SEC's website located at www.sec.gov. Copies of the preliminary prospectus supplement and accompanying prospectus relating to the public offering may be obtained, when available, by contacting Maxim Group LLC, 300 Park Avenue, New York, NY 10022, or by telephone at (212) 895-3745, or by email at [email protected]. Before you invest, you should read the preliminary prospectus supplement and accompanying prospectus, together with the information incorporated therein, for more complete information about NuZee and the proposed offering. The final terms of the offering will be disclosed in a final prospectus supplement to be filed with the SEC.

This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

You May Also Be Interested In

• Amylyx prices $500M stock offering at $35.50 per share
• FDA grants accelerated approval to Ultragenyx gene therapy for GSDIa
• Edesa Biotech launches public offering of common shares